NATURE OF BUSINESS (Details) |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 25, 2022 |
Apr. 20, 2022
shares
|
Nov. 11, 2021
$ / shares
shares
|
Sep. 03, 2021
USD ($)
|
Jul. 09, 2021
USD ($)
|
Dec. 07, 2020
USD ($)
|
Jun. 30, 2020
shares
|
Jan. 19, 2017
USD ($)
shares
|
Jul. 31, 2021
USD ($)
|
Mar. 31, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Sep. 30, 2024
USD ($)
|
Mar. 31, 2026
USD ($)
|
Mar. 31, 2025
USD ($)
|
Nov. 11, 2025 |
Jun. 30, 2024
USD ($)
|
Nov. 26, 2022
USD ($)
|
Nov. 15, 2021
shares
|
Nov. 04, 2021 |
Apr. 06, 2021 |
Feb. 04, 2021 |
|
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Stock Issued During Period, Shares, Acquisitions (in Shares) | shares | 510,000,000 | 16,155,746,000 | |||||||||||||||||||||||
| Proceeds from Sales of Business, Affiliate and Productive Assets | $ 100 | ||||||||||||||||||||||||
| Payments to Acquire Investments | $ 50,000 | ||||||||||||||||||||||||
| Number of Units in Real Estate Property | 53 | ||||||||||||||||||||||||
| Number of Real Estate Properties | 19 | ||||||||||||||||||||||||
| SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross | $ 7,626,286.37 | ||||||||||||||||||||||||
| Payments to Acquire Real Estate | $ 7,000,000 | ||||||||||||||||||||||||
| Real Estate, Description of Terms | (i)$1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. | ||||||||||||||||||||||||
| Class of Warrant or Rights, Granted (in Shares) | shares | 500,000 | ||||||||||||||||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.01 | ||||||||||||||||||||||||
| Warrants and Rights Outstanding, Term | 24 months | ||||||||||||||||||||||||
| Stock Issued During Period, Shares, New Issues (in Shares) | shares | 500,000 | ||||||||||||||||||||||||
| Investment Owned, Balance, Shares (in Shares) | shares | 20,000,000 | ||||||||||||||||||||||||
| Agreement, Description | The Company A agrees that if the patent is sold or transferred, Men Hwei Tsai or Men Hwei, Tsai’s successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei Tsai is entitled to commission equaling to 8% of sales price. | ||||||||||||||||||||||||
| Other Commitment | $ 34,978.48 | ||||||||||||||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $ (166,216) | $ 1,112,684 | $ (85,363) | $ (222,196) | $ (158,377) | $ (193,702) | $ (146,967) | $ 861,105 | $ (499,046) | ||||||||||||||||
| Cash Provided by (Used in) Operating Activity, Including Discontinued Operation | (80,272) | (60,297) | |||||||||||||||||||||||
| Equity, Including Portion Attributable to Noncontrolling Interest | (4,880,635) | $ (4,715,116) | $ (5,829,109) | (5,743,827) | (5,523,154) | $ (5,389,922) | $ (5,202,816) | (4,880,635) | (5,523,154) | $ (5,125,144) | |||||||||||||||
| Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | $ 29,346 | $ 44,056 | $ 36,880 | $ 29,346 | $ 36,880 | $ 54,943 | |||||||||||||||||||
| Corporate Joint Venture [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Payments to Acquire Interest in Joint Venture | $ 4,200,000 | ||||||||||||||||||||||||
| Co-venturer [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease) | $ 100,000 | ||||||||||||||||||||||||
| Purecell Group [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 51.00% | 51.00% | 51.00% | 51.00% | |||||||||||||||||||||
| JV Company [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 60.00% | ||||||||||||||||||||||||
| Brilliant Healthcare Limited [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 40.00% | ||||||||||||||||||||||||
| Nutrature Health LLC [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 100.00% | ||||||||||||||||||||||||
| Gof Biotechnologies, Inc. [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 100.00% | ||||||||||||||||||||||||
| International Institute of Great Health, Inc. (IIGH) [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 100.00% | ||||||||||||||||||||||||
| Common Stock [Member] | Co-venturer [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Payments to Acquire Interest in Joint Venture | $ 15,000,000 | ||||||||||||||||||||||||
| Cash Distribution [Member] | Co-venturer [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Payments to Acquire Interest in Joint Venture | $ 3,000,000 | ||||||||||||||||||||||||
| Gof Biotechnologies, Inc. [Member] | |||||||||||||||||||||||||
| NATURE OF BUSINESS (Details) [Line Items] | |||||||||||||||||||||||||
| Subsidiary, Ownership Percentage, Parent | 75.00% | ||||||||||||||||||||||||
| Investment Owned, Balance, Shares (in Shares) | shares | 60,000,000 | ||||||||||||||||||||||||
| Subsidiary, Ownership Percentage, Noncontrolling Owner | 25.00% | ||||||||||||||||||||||||